Cas no 22494-42-4 (Diflunisal)
Diflunisal Chemical and Physical Properties
Names and Identifiers
-
- diflunisal
- 5-(2,4-Difluorophenyl) salicylic acid
- 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
- 5-[2,4-DIFLUOROPHENYL]SALICYLIC ACID
- [14C]-Diflunisal
- 2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
- 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid
- 2-hydroxy-5-(2',4'-difluorophenyl)benzoic acid
- 4',6'-difluoro-4-hydroxybiphenyl-3-carboxylic acid
- Adomal
- Diflunisalum
- Dolobid
- Dolobis
- Flovacil
- Fluniget
- Fluodonil
- Flustar
- 2′,4′-Difluoro-4-hydroxy-[1,1′-biphenyl]-3-carboxylic acid
- 5-(2,4-Difluorophenyl)salicylic acid
- Difludol
- Citidol
- Noaldol
- Algobid
- Unisal
- Reuflos
- Diflusinal
- Dolisal
- Dolobil
- MK 647
- Diflunisalum [INN-Latin]
- 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid
- [1,1'-Biphenyl]-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-
- MK-647
- NCGC00016765-02
- 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID
- EINECS 245-034-9
- KBio2_006578
- BDBM50240510
- SPBio_002058
- HMS3259G17
- NCGC00016765-08
- (1,1'-Biphenyl)-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-
- Diflunisal (JAN/USP/INN)
- Diflunisal, United States Pharmacopeia (USP) Reference Standard
- HMS502O20
- SMR000058723
- CHEMBL898
- 2',4'-difluoro-4-hydroxy-biphenyl-3-carboxylic acid
- Spectrum2_001012
- BIDD:GT0063
- BSPBio_000137
- HY-18342
- 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid
- Tox21_110598
- KBio1_000938
- BPBio1_000151
- 7C546U4DEN
- KS-1346
- NSC 756728
- Diflunisalum (INN-Latin)
- N02BA11
- KBioSS_001442
- DIFLUNISAL [JAN]
- Prestwick_168
- Spectrum5_000901
- SPECTRUM1500245
- IDI1_000938
- EN300-3232727
- KBio3_001423
- 2',4'-Difluoro-4-hydroxy[1,1'-biphenyl]-3-carboxylic acid
- Tox21_110598_1
- SR-01000003165-3
- KBio2_004010
- NCGC00022783-04
- KBio2_001442
- HMS3885H10
- BRN 2654431
- HMS1568G19
- Diflunisal (USAN:USP:INN:BAN:JAN)
- AB00051969-12
- NCGC00016765-06
- NSC-756728
- DIFLUNISAL (USP MONOGRAPH)
- DIFLUNISAL (EP IMPURITY)
- D00130
- NC00506
- 5-(2,4-difluorophenyl)-2-hydroxy-benzoic acid;Diflunisal
- Diflunisal, European Pharmacopoeia (EP) Reference Standard
- Prestwick2_000039
- NCGC00016765-03
- 1286107-99-0
- DIFLUNISAL (USP-RS)
- NSC756728
- DIFLUNISAL [INN]
- BRD-K22031190-001-13-7
- SR-01000003165
- DIFLUNISAL [USP MONOGRAPH]
- NS00009099
- s4609
- DIFLUNISAL [MART.]
- HMS2091M20
- NCGC00016765-05
- CCG-40230
- SBI-0051347.P003
- CS-0007468
- MFCD00057834
- DIFLUNISAL [ORANGE BOOK]
- HMS3712G19
- 2',4'-difluoro-4-hydroxybipheny-3-carboxylic acid
- J-014739
- Diflunisal [USAN:USP:INN:BAN:JAN]
- DTXCID702932
- 2 inverted exclamation mark ,4 inverted exclamation mark -Difluoro-4-hydroxybiphenyl-3-carboxylic Acid
- NINDS_000938
- Opera_ID_803
- DIFLUNISAL (USP IMPURITY)
- Spectrum3_000392
- 3-BIPHENYLCARBOXYLIC ACID, 2',4'-DIFLUORO-4-HYDROXY-
- NCGC00016765-01
- 22494-42-4
- DB00861
- Prestwick1_000039
- FT-0630487
- DIFLUNISAL [MI]
- HMS2095G19
- C01691
- 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid
- Dolobid (TN)
- BCP09905
- Spectrum4_000513
- DIFLUNISAL [USP-RS]
- DIFLUNISAL [VANDF]
- Spectrum_000962
- SPBio_001163
- GTPL7162
- SR-01000003165-2
- SCHEMBL4337
- A816230
- Prestwick0_000039
- SY106650
- Diflunisal, analytical standard
- DIFLUNISAL [USP IMPURITY]
- Prestwick3_000039
- D5875
- 1FL
- NCGC00022783-03
- DivK1c_000938
- Pharmakon1600-01500245
- MLS001146895
- DIFLUNISAL (MART.)
- AKOS005762917
- CHEBI:39669
- MK647
- AB00051969_13
- BRD-K22031190-001-05-3
- NCGC00016765-04
- KBioGR_001085
- 2',4'-Difluoro-4-hydroxy-(1',1-diphenyl)-3-carboxylic acid
- DIFLUNISAL [EP IMPURITY]
- HMS1920G10
- DIFLUNISAL [WHO-DD]
- NCGC00016765-09
- HMS2090C16
- CAS-22494-42-4
- DTXSID5022932
- UNII-7C546U4DEN
- BSPBio_002203
- MLS000028678
- DIFLUNISAL [USAN]
- AB00051969
- Q2602750
- 2'-4'-Difluoro-4-hydroxybiphenyl-3-carboxylic acid
- GLXC-20635
- BRD-K22031190-001-23-6
- DB-045934
- Diflunisal
-
- MDL： MFCD00057834
- Inchi： 1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
- InChI Key： HUPFGZXOMWLGNK-UHFFFAOYSA-N
- SMILES： FC1C=C(C=CC=1C1C=CC(=C(C(=O)O)C=1)O)F
Computed Properties
- Exact Mass: 250.04400
- Monoisotopic Mass: 250.044151
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 18
- Rotatable Bond Count: 2
- Complexity: 311
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 4
- XLogP3: 4.4
- Topological Polar Surface Area: 57.5
Experimental Properties
- Color/Form: White solid
- Density: 1.437
- Melting Point: 210-211°C
- Boiling Point: 390
- Flash Point: 188
- Refractive Index: 1.601
- PSA: 57.53000
- LogP: 3.03560
Diflunisal Security Information
-
Symbol:
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H335-H361
- Warning Statement： P261-P281-P305 + P351 + P338
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：3
- Hazard Category Code： 63-22-36/37/38
- Safety Instruction： S22-S26-S36
- RTECS：DV2030000
-
Hazardous Material Identification：
- Safety Term：S22;S26;S36
- Toxicity：LD50 orally in female mice: 439 mg/kg (Stone)
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
- Risk Phrases：R22; R36/37/38; R63
Diflunisal Customs Data
- HS CODE：2918290000
- Customs Data：
China Customs Code:
2922299090Overview:
2922299090. Other amino groups(naphthol\phenol)And ether\Esters [including their salts, Except those containing more than one oxygen-containing group]. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:30.0%
Declaration elements:
Product Name, component content, use to, The color of ethanolamine and its salt should be reported, The package of ethanolamine and its salt shall be declared
Summary:
2922299090. other amino-naphthols and other amino-phenols, other than those containing more than one kind of oxygen function, their ethers and esters; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%
Diflunisal Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd. | D5875-25G |
Diflunisal |
22494-42-4 | >98.0%(GC) | 25g |
￥850.00 | 2024-04-17 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | D133115-1g |
Diflunisal |
22494-42-4 | ≥98% | 1g |
￥29.90 | 2023-09-03 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | D133115-5g |
Diflunisal |
22494-42-4 | ≥98% | 5g |
￥112.90 | 2023-09-03 | |
| S e l l e c k ZHONG GUO | S4609-100mg |
Diflunisal |
22494-42-4 | 99.99% | 100mg |
￥795.33 | 2023-09-15 | |
| S e l l e c k ZHONG GUO | S4609-500mg |
Diflunisal |
22494-42-4 | 99.99% | 500mg |
￥2432.64 | 2023-09-15 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R019014-1g |
Diflunisal |
22494-42-4 | 98% | 1g |
￥26 | 2024-05-24 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R019014-5g |
Diflunisal |
22494-42-4 | 98% | 5g |
￥89 | 2024-05-24 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R019014-25g |
Diflunisal |
22494-42-4 | 98% | 25g |
￥436 | 2024-05-24 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R019014-100g |
Diflunisal |
22494-42-4 | 98% | 100g |
￥1823 | 2024-05-24 | |
| ChemScence | CS-0007468-10g |
Diflunisal |
22494-42-4 | 99.91% | 10g |
$40.0 | 2022-04-27 |
Diflunisal Suppliers
Audited Supplier
Diflunisal Related Literature
-
Torsten Kniess,Markus Laube,Frank Wüst,Jens Pietzsch Dalton Trans. 2017 46 14435
-
Mohammed Amir Husain,Sayeed Ur Rehman,Hassan Mubarak Ishqi,Tarique Sarwar,Mohammad Tabish RSC Adv. 2015 5 64335
-
Davide Carta,Paola Brun,Matteo Dal Pra,Giulia Bernabè,Ignazio Castagliuolo,Maria Grazia Ferlin Med. Chem. Commun. 2018 9 1017
-
David O. Abe,Arvin Eskandari,Kogularamanan Suntharalingam Dalton Trans. 2018 47 13761
-
António O. L. évora,Ricardo A. E. Castro,Teresa M. R. Maria,M. Ramos Silva,J. H. ter Horst,Jo?o Canotilho,M. Ermelinda S. Eusébio CrystEngComm 2016 18 4749
Additional information on Diflunisal
Diflunisal (CAS No. 22494-42-4): A Comprehensive Overview in Modern Pharmaceutical Research
Diflunisal, chemically designated as 2-(p-chlorophenyl)-5-(2,4-dichlorophenyl)benzoic acid, is a well-established nonsteroidal anti-inflammatory drug (NSAID) widely recognized for its therapeutic efficacy in managing mild to moderate pain and inflammation. With a CAS number of 22494-42-4, this compound has been the subject of extensive research and clinical studies, contributing significantly to the understanding of its pharmacological mechanisms and applications in contemporary medicine.
The molecular structure of Diflunisal features a benzoic acid core substituted with a p-chlorophenyl group at the 2-position and a 2,4-dichlorophenyl group at the 5-position. This unique arrangement contributes to its distinct pharmacokinetic properties, including a relatively long half-life compared to other NSAIDs, which allows for less frequent dosing. The compound's chemical stability and solubility profile have also been optimized for various pharmaceutical formulations, enhancing its bioavailability and therapeutic effectiveness.
In recent years, research on Diflunisal has expanded beyond its traditional applications in pain management. Studies have explored its potential role in modulating inflammatory pathways, which may have implications for the treatment of chronic inflammatory conditions such as rheumatoid arthritis and osteoarthritis. The compound's ability to inhibit cyclooxygenase (COX) enzymes, particularly COX-1 and COX-2, has been a focal point of investigation. Unlike some traditional NSAIDs, Diflunisal has shown a relatively lower risk of gastrointestinal side effects, making it a promising candidate for long-term therapeutic use.
Advances in computational chemistry and molecular modeling have furthered the understanding of Diflunisal's interactions with biological targets. These studies have revealed insights into how the compound binds to COX enzymes and other potential receptors, providing a foundation for the development of novel derivatives with improved pharmacological profiles. Additionally, the exploration of Diflunisal's metabolic pathways has uncovered new opportunities for enhancing its therapeutic window and reducing adverse effects.
One of the most intriguing areas of research involving Diflunisal is its potential anti-cancer properties. Preliminary studies have suggested that the compound may exhibit inhibitory effects on certain cancer cell lines by modulating key signaling pathways involved in tumor growth and progression. Specifically, research has indicated that Diflunisal can interfere with the activity of enzymes such as lipoxygenase and cyclooxygenase, which play critical roles in cancer cell proliferation. While these findings are still in the early stages, they highlight the compound's potential as a multitargeted therapeutic agent.
The pharmacological versatility of Diflunisal has also prompted investigations into its use as an adjuvant therapy in combination with other medications. For instance, studies have examined its synergistic effects when used alongside conventional treatments for pain management disorders. These combination therapies aim to improve patient outcomes by leveraging the complementary mechanisms of action of different drugs. Such approaches are particularly relevant in chronic conditions where long-term treatment is necessary.
From a regulatory perspective, the safety and efficacy of Diflunisal have been thoroughly evaluated through numerous clinical trials conducted across various populations. These trials have provided robust evidence supporting its use in treating inflammatory conditions while minimizing risks associated with long-term NSAID therapy. Regulatory agencies continue to monitor post-marketing data to ensure that Diflunisal remains a safe and effective option for patients worldwide.
The future direction of research on Diflunisal is likely to focus on optimizing its formulations for better patient compliance and exploring novel therapeutic applications. Innovations in drug delivery systems may enhance the compound's bioavailability and reduce gastrointestinal irritation, further improving its clinical utility. Additionally, ongoing investigations into its anti-inflammatory and potential anti-cancer properties may uncover new indications for this versatile compound.
In conclusion, Diflunisal (CAS No. 22494-42-4) represents a significant advancement in NSAID therapy due to its unique chemical structure, favorable pharmacokinetic profile, and broad spectrum of potential applications. The continued exploration of its mechanisms of action and therapeutic benefits ensures that it remains a valuable asset in modern pharmaceutical research. As scientific understanding evolves, Diflunisal is poised to play an increasingly important role in addressing diverse medical challenges.
22494-42-4 (Diflunisal) Related Products
- 85665-84-5(potassium 2',4'-difluoro-4-hydroxy[1,1'-biphenyl]-3-carboxylate)
- 1261910-55-7(4-fluoro-3-(2-hydroxyphenyl)benzoic Acid)
- 1261922-06-8(4-(2,6-Difluorophenyl)-2-hydroxybenzoic acid)
- 1261927-03-0(4-(5-Carboxy-2-fluorophenyl)-2-hydroxybenzoic acid)
- 138473-86-6([1,1'-Biphenyl]-3-carboxylicacid, 2',4'-difluoro-4,5-dihydroxy-)
- 1261890-72-5(4-(2,4-Difluorophenyl)-3-hydroxybenzoic acid)
- 84145-00-6([1,1'-Biphenyl]-3-carboxylicacid, 2',4'-difluoro-4-hydroxy-, sodium salt (1:1))
- 1261915-97-2(4-(2-Fluoro-5-methylphenyl)-2-hydroxybenzoic acid)
- 1214376-93-8(4-(2-fluorophenyl)-2-hydroxybenzoic Acid)
- 1262008-49-0(2-hydroxy-4-(2,4,6-trifluorophenyl)benzoic Acid)
